Baylor College of Medicine

A Trial to Evaluate Tavapadon in Early Parkinson's Disease (H-46873)



A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Flexible Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease.  Tavapadon is a partial agonist of the dopamine D1-like receptors with high specificity for the D1 and D5 receptor subtypes.  Open extension study to follow. 

If you or a loved one have been diagnosed with Parkinson's disease (PD), you or your loved one may be interested in participating in one of the TemPo Studies.  They are a suite of three clinical research studies evaluating an oral investigational drug (tavapadon) to see if it may help improve PD symptoms that impact your movement and daily activities.  

You may be eligible to participate if you meet the following eligibility criteria:

  • have been diagnosed with PD
  • are 40 to 80 years of age
  • have never received deep brain stimulation treatment.


Rory Mahabir

Phone 1: 713–798–5989

IRB: H-46873




Back to topback-to-top